Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + nonpegylated liposomal doxorubicin + trastuzumab
- Development stage
- Unknown
- Lead developer
- Sopherion Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of cyclophosphamide, nonpegylated liposomal doxorubicin (NPLD), and trastuzumab. This regimen is used primarily for the treatment of HER2-positive breast cancer. The nonpegylated liposomal formulation of doxorubicin offers reduced cardiotoxicity compared to conventional doxorubicin while maintaining efficacy. Trastuzumab targets HER2 receptors on cancer cells, while cyclophosphamide and doxorubicin provide cytotoxic effects. This combination is typically administered sequentially, with cyclophosphamide and NPLD followed by trastuzumab, often with a taxane.
02
Targets
TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA
Beyond the preview
Go deeper on cyclophosphamide + nonpegylated liposomal doxorubicin + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + nonpegylated liposomal doxorubicin + trastuzumab.